Damon Dierker, OD: No relevant disclosure to display
This course reviews new topical therapies for presbyopia and dry eye disease, including pilocarpine 0.4%, aceclidine, and TRPM8 agonists. Mechanisms of action, clinical trial outcomes, safety profiles, and patient selection strategies will be discussed to help clinicians integrate these therapies into contemporary anterior segment care.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Describe the mechanisms of action and clinical trial outcomes of new topical miotics for presbyopia, including pilocarpine 0.4% and aceclidine.
Evaluate the role of neuromodulation in dry eye therapy, with emphasis on investigational TRPM8 agonists such as acoltremon.
Identify appropriate patient selection criteria, contraindications, and risk factors when prescribing emerging anterior segment therapies.
